ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 270 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $283,772,861 | -14.5% | 13,616,740 | -1.7% | 0.01% | -12.5% |
Q2 2023 | $331,823,561 | +28.9% | 13,854,846 | +1.3% | 0.01% | +14.3% |
Q1 2023 | $257,435,185 | +21.8% | 13,678,809 | +3.0% | 0.01% | +16.7% |
Q4 2022 | $211,414,018 | -0.0% | 13,279,775 | +2.7% | 0.01% | 0.0% |
Q3 2022 | $211,463,000 | +21.0% | 12,925,641 | +4.2% | 0.01% | +20.0% |
Q2 2022 | $174,724,000 | -42.7% | 12,400,593 | -1.4% | 0.01% | -28.6% |
Q1 2022 | $304,707,000 | +6.0% | 12,580,814 | +2.2% | 0.01% | 0.0% |
Q4 2021 | $287,441,000 | +42.7% | 12,315,366 | +1.5% | 0.01% | +40.0% |
Q3 2021 | $201,468,000 | -28.3% | 12,129,266 | +5.3% | 0.01% | -28.6% |
Q2 2021 | $280,932,000 | +0.3% | 11,518,317 | +6.1% | 0.01% | -12.5% |
Q1 2021 | $280,218,000 | -50.6% | 10,861,175 | +2.4% | 0.01% | -50.0% |
Q4 2020 | $566,984,000 | +32.6% | 10,605,773 | +2.3% | 0.02% | +14.3% |
Q3 2020 | $427,750,000 | -17.2% | 10,369,690 | -2.7% | 0.01% | -22.2% |
Q2 2020 | $516,759,000 | +11.4% | 10,661,419 | -2.9% | 0.02% | -10.0% |
Q1 2020 | $464,033,000 | +2.2% | 10,983,037 | +3.5% | 0.02% | +33.3% |
Q4 2019 | $454,179,000 | +20.1% | 10,616,613 | +1.0% | 0.02% | +7.1% |
Q3 2019 | $378,278,000 | +48.9% | 10,510,624 | +10.6% | 0.01% | +40.0% |
Q2 2019 | $254,071,000 | -0.4% | 9,505,082 | +0.1% | 0.01% | 0.0% |
Q1 2019 | $255,012,000 | +55.5% | 9,497,642 | -6.4% | 0.01% | +42.9% |
Q4 2018 | $163,990,000 | -10.5% | 10,141,664 | +14.9% | 0.01% | 0.0% |
Q3 2018 | $183,303,000 | +38.4% | 8,829,618 | +1.8% | 0.01% | +16.7% |
Q2 2018 | $132,459,000 | -27.7% | 8,674,446 | +6.4% | 0.01% | -25.0% |
Q1 2018 | $183,270,000 | -23.8% | 8,156,164 | +2.1% | 0.01% | -27.3% |
Q4 2017 | $240,434,000 | -17.9% | 7,985,197 | +2.7% | 0.01% | -21.4% |
Q3 2017 | $292,752,000 | +38.0% | 7,771,508 | +2.2% | 0.01% | +40.0% |
Q2 2017 | $212,093,000 | -17.4% | 7,604,605 | +1.8% | 0.01% | -23.1% |
Q1 2017 | $256,812,000 | +25.0% | 7,469,785 | +4.9% | 0.01% | +18.2% |
Q4 2016 | $205,388,000 | -6.0% | 7,121,644 | +3.7% | 0.01% | -15.4% |
Q3 2016 | $218,502,000 | +5.7% | 6,868,996 | +7.9% | 0.01% | 0.0% |
Q2 2016 | $206,737,000 | +17.0% | 6,368,960 | +0.8% | 0.01% | +18.2% |
Q1 2016 | $176,694,000 | -11.5% | 6,319,539 | +12.8% | 0.01% | -15.4% |
Q4 2015 | $199,699,000 | -72.9% | 5,601,656 | -72.4% | 0.01% | -53.6% |
Q3 2015 | $737,616,000 | +232.1% | 20,268,112 | +282.2% | 0.03% | +86.7% |
Q2 2015 | $222,089,000 | +32.8% | 5,302,962 | +3.3% | 0.02% | +36.4% |
Q1 2015 | $167,231,000 | +7.9% | 5,131,359 | +5.1% | 0.01% | 0.0% |
Q4 2014 | $155,011,000 | +29.6% | 4,882,201 | +1.1% | 0.01% | +22.2% |
Q3 2014 | $119,606,000 | +9.6% | 4,830,617 | +0.0% | 0.01% | 0.0% |
Q2 2014 | $109,102,000 | -6.4% | 4,829,652 | +0.8% | 0.01% | -10.0% |
Q1 2014 | $116,538,000 | +8.1% | 4,789,894 | +11.0% | 0.01% | +11.1% |
Q4 2013 | $107,847,000 | +1.3% | 4,315,613 | +11.3% | 0.01% | -10.0% |
Q3 2013 | $106,501,000 | +100.8% | 3,877,013 | +32.7% | 0.01% | +66.7% |
Q2 2013 | $53,042,000 | – | 2,922,469 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |